Oct 9 (Reuters) - Novo Nordisk NOVOb.CO:
TO ACQUIRE AKERO THERAPEUTICS AND ITS PROMISING PHASE 3 FGF21 ANALOGUE TO EXPAND MASH PORTFOLIO
TO BUY AKERO FOR $4.7 BILLION IN CASH
AKERO'S EFRUXIFERMIN SHOWS SIGNIFICANT FIBROSIS REGRESSION IN PHASE 2
AKERO BOARD APPROVES DEAL, EXPECTED TO CLOSE YEAR-END
DEAL NOT EXPECTED TO IMPACT NOVO NORDISK'S 2025 PROFIT OUTLOOK
2025 FREE CASH FLOW OUTLOOK NEGATIVELY IMPACTED BY $4 BILLION
FOR 2026, ACQUISITION IS EXPECTED TO LEAD TO INCREASED RESEARCH AND DEVELOPMENT T COSTS
NEGATIVE IMPACT ON FY OPERATING PROFIT GROWTH IN 2026 OF AROUND 3%-POINTS
IMPLIED 2025 FREE CASH FLOW OUTLOOK IS THEREFORE 9-19 BILLION DKK DEPENDING ON TIMING OF CLOSING
2026 PROFIT GROWTH IMPACTED BY 3%-POINTS DUE TO RESEARCH AND DEVELOPMENT COSTS
TRANSACTION WILL BE MAINLY DEBT FINANCED
Further company coverage: NOVOb.CO